On page 3, the colors in the legends for Figure 2A-F are transposed. Blue should correspond to the mutated cases, and red should represent wild type. The corrected Figure 2A-F is shown below.

Figure 2.
Kaplan-Meier OS analysis for patients with newly diagnosed AML aged ≥60 years. (A-D) Survival analysis stratified by KRAS, NRAS, PTPN11, and EZH2 mutations among patients with ELN 2024 favorable- or intermediate-risk AML. (E-F) Survival analysis stratified by NPM1 and IDH mutations among patients with ELN 2024 favorable- or intermediate-risk AML with KRAS and EZH2 wild type.
View largeDownload PPT

Kaplan-Meier OS analysis for patients with newly diagnosed AML aged ≥60 years. (A-D) Survival analysis stratified by KRAS, NRAS, PTPN11, and EZH2 mutations among patients with ELN 2024 favorable- or intermediate-risk AML. (E-F) Survival analysis stratified by NPM1 and IDH mutations among patients with ELN 2024 favorable- or intermediate-risk AML with KRAS and EZH2 wild type.

Figure 2.
Kaplan-Meier OS analysis for patients with newly diagnosed AML aged ≥60 years. (A-D) Survival analysis stratified by KRAS, NRAS, PTPN11, and EZH2 mutations among patients with ELN 2024 favorable- or intermediate-risk AML. (E-F) Survival analysis stratified by NPM1 and IDH mutations among patients with ELN 2024 favorable- or intermediate-risk AML with KRAS and EZH2 wild type.
View largeDownload PPT

Kaplan-Meier OS analysis for patients with newly diagnosed AML aged ≥60 years. (A-D) Survival analysis stratified by KRAS, NRAS, PTPN11, and EZH2 mutations among patients with ELN 2024 favorable- or intermediate-risk AML. (E-F) Survival analysis stratified by NPM1 and IDH mutations among patients with ELN 2024 favorable- or intermediate-risk AML with KRAS and EZH2 wild type.

Close modal
© 2025 American Society of Hematology. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
2025